Lysosomal disruption preferentially targets acute myeloid leukemia cells and progenitors.
Sukhai MA, Prabha S, Hurren R, Rutledge AC, Lee AY, Sriskanthadevan S, Sun H, Wang X, Skrtic M, Seneviratne A, Cusimano M, Jhas B, Gronda M, MacLean N, Cho EE, Spagnuolo PA, Sharmeen S, Gebbia M, Urbanus M, Eppert K, Dissanayake D, Jonet A, Dassonville-Klimpt A, Li X, Datti A, Ohashi PS, Wrana J, Rogers I, Sonnet P, Ellis WY, Corey SJ, Eaves C, Minden MD, Wang JC, Dick JE, Nislow C, Giaever G, Schimmer AD.
Sukhai MA, et al. Among authors: rutledge ac.
J Clin Invest. 2013 Jan;123(1):315-28. doi: 10.1172/JCI64180. Epub 2012 Dec 3.
J Clin Invest. 2013.
PMID: 23202731
Free PMC article.
Clinical Trial.